Anna Aparicio

Enantioselective synthesis of levomilnacipran

Expanding the Enzyme Universe: Accessing Non‐Natural Reactions by Mechanism‐Guided Directed Evolution

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Improved Cyclopropanation Activity of Histidine‐Ligated Cytochrome P450 Enables the Enantioselective Formal Synthesis of Levomilnacipran

Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway

Induced protein degradation: an emerging drug discovery paradigm

Improved Cyclopropanation Activity of Histidine‐Ligated Cytochrome P450 Enables the Enantioselective Formal Synthesis of Levomilnacipran

Chemomimetic Biocatalysis: Exploiting the Synthetic Potential of Cofactor-Dependent Enzymes To Create New Catalysts

P450-catalyzed asymmetric cyclopropanation of electron-deficient olefins under aerobic conditions

Ausdehnung des Enzym‐Universums: Zugang zu nicht‐natürlichen Reaktionen durch mechanismusgeleitete, gerichtete Evolution

Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors

Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft